
Donato Spota appointed as chief financial officer at Eleva
Ella Day | May 14, 2025 | Appointment | Research and Development | Eleva, Pharmacy, appointment, biopharma, chief financial officer (CFO)
German biopharma company, Eleva, has appointed Donato Spota as its new chief financial officer (CFO) and managing director to support ongoing international growth.
Spota brings a wealth of experience as a senior pharma leader, specifically in strategic finance, investor relations, business development and international capital markets transactions. He has previously served as CFO at Hansa Biopharma and Basilea Pharmaceutica. Also at Basilea, he served as global head of finance and services and head of global controlling.
He will replace Danielle Püschel, who is appointed as chief accounting officer at the company. CEO of Eleva, Björn Cochlovius, commented: “The entire team is glad Danielle will continue her career with the company.”
Through its moss-based technology platform, Eleva is developing previously inaccessible biologics. Its leading candidates focus on complement disorders and enzyme replacement therapies and have entered clinical trials.
Spota’s “proven experience in financial management of rapidly growing companies makes him the ideal candidate to help us successfully navigate the ongoing transformation of Eleva,” added Cochlovius.
“I’m looking forward to working closely with Björn and the leadership team to help refine and successfully execute Eleva’s growth strategy,” said Spota.
Ella Day
14/5/25
Related Content

Symeres announces acquisition of DGr Pharma
Symeres, a Contract Research, Development and Manufacturing Organization (CRDMO) has acquired DGr Pharma, a drug …

University of Edinburgh spinout Kynos Therapeutics acquired by Dr. Falk Pharma
Kynos Therapeutics – a Scottish clinical stage biopharma company focusing on developing novel kynurenine 3-monooxygenase …

David Wheadon appointed to board of directors at Seaport Therapeutics
This week, Seaport Therapeutics have appointed David Wheadon MD to their board of directors.






